Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LYPHOMED GALLIUM NITRATE NDA TO BE FILED IN SEPTEMBER

Executive Summary

LYPHOMED GALLIUM NITRATE NDA TO BE FILED IN SEPTEMBER for treatment of cancer-related hyper-calcemia, the company announced July 7. The drug is being developed under a research agreement with patent holder Memorial Sloan-Kettering Cancer Center, which has granted LyphoMed exclusive worldwide manufacturing and marketing rights. "Gallium nitrate substantially reduces bone loss, while currently available therapies are far less effective in treating this condition and are excessively toxic," the release states. "Under the research agreement, LyphoMed will support continuing clinical research on gallium nitrate and will undertake the development of an oral form of the drug." The company said it is also planning to file an NDA for treatment of bone metastases "at a later point in time." The agreement with Sloan-Kettering marks another step in the hospital marketer's move into the brand name drug area through the leveraging of its core micronutrient and generic drug business. LyphoMed already markets one proprietary product, Pentam 300, and has at least five more under development, four as orphan drugs. At an Alex Brown health care seminar in May, LyphoMed Senior VP Richard Weiland predicted that the firm may eventually split into two divisions, one for multi-source and one for brand name products ("The Pink Sheet" May 18, T&G-6). Toward that end, the firm's specialty detail force, now at 12 reps, will be expanded to 30 by year-end. Through agreements with NovoPharm and Vestar, LyphoMed has also moved into two other new areas in 1987, oral products marketed to hospitals and liposome-delivered cancer drugs, respectively.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012163

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel